Quarter 4, 2010
Supportive Care
Diagnosis, Prognostic Factors, and Treatment Considerations
Features
Drug and Administration Compendia
Coding, reimbursement, and available therapies in Supportive Care
Special Feature
Comparative Effectiveness Raises Questions Around Cost, Data Use by Angela Maas
Departments
Correspondence
Kjel A. Johnson, PharmD, Publisher, ManagedCare Oncology
Pipeline
Howard "Skip" Burris III, MD, Director of Drug Development at Sarah Cannon Research Institute
Clinical Trails Update
John W. Mucenski, BS, PharmD, Director of Pharmacy Operations at UPMC Cancer Centers
Regulatory and Reimbursement
Espansion of Section 340B Raises New Questions for Cancer Stakeholders by Bryan Cote
